Hera Biolabs, the University of Michigan, Case Western Reverse University and other collaborators are announcing a recent publication in the American Association for Cancer Research (AACR) journal, Molecular Cancer Therapeutics, entitled, "Sprague Dawley Rag2-null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts."
While advances in in-vitro platforms have allowed researchers to better visually monitor a variety of aspects of tumor biology, a significant limitation of 3D cultured models for patient therapeutic monitoring or “patient avatars” is the lack of important components, such as the influence of surrounding tissues and potential cell-to-cell interactions, when studying cancer progression, treatment responses and outcomes. Patient derived xenograft models or PDX models overcome these limitations and other research challenges and provide a platform that is believed to more closely mimic the patient tumor.
Humanized liver mouse models are increasingly being used in preclinical [...]
First time treatment of Chronic Lymphocratic Leukemia (CLL) generally requires [...]
Despite ongoing research, lung cancers have remained among the most [...]
Hepatitis E virus (HEV) is estimated to cause more than 56 thousand deaths each year, and although most infections remain asymptomatic, HEV is still considered one of the most common causes of acute viral hepatitis and is an ongoing concern for immunosuppressed transplant patients.
Hera BioLabs (“Hera”), a Lexington KY based contract research organization [...]
Hera BioLabs and our VP of Research and Development Tseten [...]
Hera BioLabs, Inc. (Lexington KY) announced today that it has [...]
Hera BioLabs, a Lexington based contract research organization (CRO), announced [...]
